Clinical Trial

Safety Shot Continues Scientific Development with Double-Blind Placebo-Controlled Trial Designed to Assess the Effects of Safety Shot on Blood and Breath Alcohol Levels

Topline data expected Q1 2024Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and…

4 months ago

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”…

4 months ago

Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused…

4 months ago

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion…

4 months ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

4 months ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

4 months ago

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug…

4 months ago

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

4 months ago

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class…

4 months ago

Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

Virtual Event to be held on November 29, 2023 at 4:15 p.m. ETLOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) --…

4 months ago